However, the results were not consistent: patients with a higher expression of eIF3a have a better prognosis in lung cancer, esophageal cancer, ovarian cancer, cervical cancer, and bladder cancer, whereas opposite results were observed in patients with liver cancer and pancreatic cancer (Yin et al., 2018). Here, EIF3A is linked to esophageal cancer.